Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.
T Tanaka, Y Fukuta, R Higashino, R Sato, Y Nomura, Y Fukuda, S Ito, M Takei, T Kurimoto, H Tamaki
Index: Eur. J. Pharmacol. 357(1) , 53-60, (1998)
Full Text: HTML
Abstract
We investigated the pharmacological characteristics of Z-335 ((+/-)-sodium[2-[4-(chlorophenylsulfonylaminomethyl)indan-5-yl]ace tate monohydrate), a new indan derivative. Z-335 inhibited the specific binding of [3H]SQ-29548 to human platelets and guinea pig platelet membranes. The IC50 values of Z-335 for human platelets and guinea pig platelet membranes were 29.9 +/- 3.1 nM with a slope of 1.09 +/- 0.05 and 32.5 +/- 1.7 nM with a slope of 1.07 +/- 0.02, respectively. Z-335 inhibited thromboxane A2 receptor-mediated human and guinea pig platelet aggregation in vitro and oral administration of this drug to guinea pigs inhibited U-46619- and collagen-induced platelet aggregation for 24 h. Z-335 dose-dependently prevented the occurrence of U-46619-induced pulmonary thromboembolism in mice and the protective effect of this drug (0.3 and 3 mg/kg, p.o.) lasted for 24 h. These results strongly suggest that Z-335 is a potent, orally active and long-lasting thromboxane A2 receptor antagonist, which may be useful as an antiplatelet drug.
Related Compounds
Related Articles:
2012-08-01
[Acta Physiol. (Oxf.) 205(4) , 507-19, (2012)]
2002-01-01
[Thromb. Haemost. 87(1) , 114-21, (2002)]
1999-08-01
[Hepatology 30 , 454-461, (1999)]
2011-11-01
[Am. J. Physiol. Heart Circ. Physiol. 301(5) , H2140-6, (2011)]
2003-12-01
[Lab. Invest. 83(12) , 1733-41, (2003)]